Compare Charles Schwab Corporation Common Stock (SCHW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs TransMedics Group Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 61.1× TransMedics Group Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and TransMedics Group Inc for 24 Days on average.
| SCHW | TMDX | |
|---|---|---|
Market Cap | $167.52B | $2.74B |
Volume | 6,554,126 | 949,331 |
Sector | Financials | Health |
52-Week High | $113.65 | $150.42 |
52-Week Low | $85.35 | $61.99 |
Typical Hold Time | 85 Days | 24 Days |
Enterprise Value | $153.97B | $3.13B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 1.35% with strong fundamentals including 37% net margin and consistent earnings beats. Technical indicators show bearish momentum near key support at $96, while fundamentals reveal robust revenue growth to $23.92B in 2025 and improving cash flow. The company demonstrates operational strength with client assets reaching $13.41T in August 2026 and strategic AI integration with Anthropic.
Outlook remains positive with 56.9% analyst buy ratings and $120.33 consensus target, though near-term technical weakness and competitive pressures pose risks. Earnings momentum and market share gains in the growing e-brokerage sector support upside potential, while interest rate sensitivity and execution risks require monitoring.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
